COMMUNIQUÉS West-GlobeNewswire

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
04/04/2024
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals [...]
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
04/04/2024
SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent [...]
Central Georgia Cancer Care Joins American Oncology Network to Elevate Local Cancer Care Delivery
04/04/2024
MACON, Ga., April 04, 2024 (GLOBE NEWSWIRE) -- Central Georgia Cancer Care is excited to announce their partnership with the American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks [...]
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
04/04/2024
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers Based on subsequent positive randomized data, Company preparing [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2024
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced [...]
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
04/04/2024
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody candidate to enter the clinic developed to [...]
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
04/04/2024
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, [...]
Healthcare Triangle Announces Strategic Partnership with Cynomi to Enhance Cybersecurity in Healthcare
04/04/2024
PLEASANTON, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leading provider of healthcare IT solutions, is thrilled to announce [...]
Extendicare Announces Timing of 2024 First Quarter Results and Conference Call
04/04/2024
MARKHAM, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the first quarter of 2024 after market [...]
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
04/04/2024
Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in borderline resectable [...]
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
04/04/2024
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data show that inhibiting [...]
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
04/04/2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target [...]
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
04/04/2024
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable [...]
BrightSpring Health Services Applauds Hundreds of Award-Winning Employees for their Recognition of Outstanding Service and Care
04/04/2024
LOUISVILLE, Ky., April 04, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or “the Company”) (NASDAQ: BTSG) applauds its most recent employees and programs for their dedicated service, care, [...]
HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations
04/04/2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce further expansion of HealthTab™ with Rexall [...]
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
04/04/2024
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human [...]
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
04/04/2024
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief [...]
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
04/04/2024
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
04/04/2024
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs [...]

Pages